The stock of Guardant Health Inc (GH) has gone down by -3.65% for the week, with a -11.92% drop in the past month and a 37.18% rise in the past quarter. The volatility ratio for the week is 5.58%, and the volatility levels for the past 30 days are 4.70% for GH. The simple moving average for the past 20 days is -9.72% for GH’s stock, with a 19.94% simple moving average for the past 200 days.
Is It Worth Investing in Guardant Health Inc (NASDAQ: GH) Right Now?
Moreover, the 36-month beta value for GH is 1.26. Analysts have varying opinions on the stock, with 14 analysts rating it as a “buy,” 7 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for GH is 117.85M and currently, short sellers hold a 7.00% of that float. On December 26, 2024, GH’s average trading volume was 1.72M shares.
GH) stock’s latest price update
The stock of Guardant Health Inc (NASDAQ: GH) has decreased by -1.24 when compared to last closing price of 31.57.Despite this, the company has seen a loss of -3.65% in its stock price over the last five trading days. businesswire.com reported 2024-12-20 that PALO ALTO, Calif. & TAMPA, Fla.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Meaningful Insights Biotech Analytics (MiBA), an innovative healthcare technology company, today announced a unique partnership aimed at optimizing the use of biomarker testing and data analytics to advance precision medicine in patient care throughout the MiBA Network. Recognizing the evolving landscape of precision medicine, the collaboration combines MiBA’s cutting-.
Analysts’ Opinion of GH
Many brokerage firms have already submitted their reports for GH stocks, with Guggenheim repeating the rating for GH by listing it as a “Buy.” The predicted price for GH in the upcoming period, according to Guggenheim is $36 based on the research report published on June 28, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see GH reach a price target of $32. The rating they have provided for GH stocks is “Buy” according to the report published on June 03rd, 2024.
Craig Hallum gave a rating of “Buy” to GH, setting the target price at $28 in the report published on April 24th of the current year.
GH Trading at 5.91% from the 50-Day Moving Average
After a stumble in the market that brought GH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.08% of loss for the given period.
Volatility was left at 4.70%, however, over the last 30 days, the volatility rate increased by 5.58%, as shares sank -9.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +44.81% upper at present.
During the last 5 trading sessions, GH fell by -3.52%, which changed the moving average for the period of 200-days by +64.40% in comparison to the 20-day moving average, which settled at $34.54. In addition, Guardant Health Inc saw 15.27% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GH starting from Tariq Musa, who sale 116 shares at the price of $34.85 back on Dec 18 ’24. After this action, Tariq Musa now owns 2,810 shares of Guardant Health Inc, valued at $4,043 using the latest closing price.
Tariq Musa, the Director of Guardant Health Inc, proposed sale 116 shares at $34.85 during a trade that took place back on Dec 18 ’24, which means that Tariq Musa is holding shares at $4,043 based on the most recent closing price.
Stock Fundamentals for GH
Current profitability levels for the company are sitting at:
- -0.74 for the present operating margin
- 0.81 for the gross margin
The net margin for Guardant Health Inc stands at -0.74. The total capital return value is set at -0.38. Equity return is now at value -609.28, with -30.72 for asset returns.
Based on Guardant Health Inc (GH), the company’s capital structure generated 1.06 points at debt to capital in total, while cash flow to debt ratio is standing at -0.22. The debt to equity ratio resting at -19.0. The interest coverage ratio of the stock is -199.59.
Currently, EBITDA for the company is -433.31 million with net debt to EBITDA at -1.39. When we switch over and look at the enterprise to sales, we see a ratio of 6.52. The receivables turnover for the company is 7.83for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.22.
Conclusion
To wrap up, the performance of Guardant Health Inc (GH) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
